These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31025094)

  • 1. The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype.
    Veenstra C; Karlsson E; Mirwani SM; Nordenskjöld B; Fornander T; Pérez-Tenorio G; Stål O
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1845-1856. PubMed ID: 31025094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer.
    Karlsson E; Veenstra C; Emin S; Dutta C; Pérez-Tenorio G; Nordenskjöld B; Fornander T; Stål O
    Breast Cancer Res Treat; 2015 Aug; 153(1):31-40. PubMed ID: 26208487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer.
    Karlsson E; Veenstra C; Gårsjö J; Nordenskjöld B; Fornander T; Stål O
    J Cancer Res Clin Oncol; 2019 Mar; 145(3):599-607. PubMed ID: 30515568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers.
    Shields BJ; Wiede F; Gurzov EN; Wee K; Hauser C; Zhu HJ; Molloy TJ; O'Toole SA; Daly RJ; Sutherland RL; Mitchell CA; McLean CA; Tiganis T
    Mol Cell Biol; 2013 Feb; 33(3):557-70. PubMed ID: 23166300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cell type-specific role of protein tyrosine phosphatase non-receptor type 2 in regulating ER stress signalling.
    Kasper SH; Spalinger MR; Raselli T; Scharl M
    Digestion; 2015; 91(3):248-56. PubMed ID: 25823847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TYRO3 as a potential therapeutic target in breast cancer.
    Ekyalongo RC; Mukohara T; Funakoshi Y; Tomioka H; Kataoka Y; Shimono Y; Chayahara N; Toyoda M; Kiyota N; Minami H
    Anticancer Res; 2014 Jul; 34(7):3337-45. PubMed ID: 24982338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
    Liu ZF; Chen C; Yao XL; Sun SR
    Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection of epithelial barrier function by the Crohn's disease associated gene protein tyrosine phosphatase n2.
    Scharl M; Paul G; Weber A; Jung BC; Docherty MJ; Hausmann M; Rogler G; Barrett KE; McCole DF
    Gastroenterology; 2009 Dec; 137(6):2030-2040.e5. PubMed ID: 19818778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 25-Hydroxyvitamin D
    Zhang P; Zhang W; Zhang D; Wang M; Aprecio R; Ji N; Mohamed O; Li Y; Ding Y; Wang Q
    J Periodontal Res; 2018 Jun; 53(3):467-477. PubMed ID: 29516520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
    Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
    J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
    Wu SY; Tan Y; Guan YS
    Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas.
    Wang PF; Cai HQ; Zhang CB; Li YM; Liu X; Wan JH; Jiang T; Li SW; Yan CX
    J Neuroinflammation; 2018 May; 15(1):145. PubMed ID: 29764444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTPN2 regulates the activation of KRAS and plays a critical role in proliferation and survival of KRAS-driven cancer cells.
    Huang Z; Liu M; Li D; Tan Y; Zhang R; Xia Z; Wang P; Jiao B; Liu P; Ren R
    J Biol Chem; 2020 Dec; 295(52):18343-18354. PubMed ID: 33122197
    [No Abstract]   [Full Text] [Related]  

  • 14. Met and its ligand HGF are associated with clinical outcome in breast cancer.
    Veenstra C; Pérez-Tenorio G; Stelling A; Karlsson E; Mirwani SM; Nordensköljd B; Fornander T; Stål O
    Oncotarget; 2016 Jun; 7(24):37145-37159. PubMed ID: 27175600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different prognosis of young breast cancer patients in their 20s and 30s depending on subtype: a nationwide study from the Korean Breast Cancer Society.
    Ryu JM; Yu J; Kim SI; Kim KS; Moon HG; Choi JE; Jeong J; Do Byun K; Nam SJ; Lee JE; Lee SK; Kim SW
    Breast Cancer Res Treat; 2017 Dec; 166(3):833-842. PubMed ID: 28831642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulated PTPN2 induced by inflammatory response or oxidative stress stimulates the progression of thyroid cancer.
    Zhang Z; Xu T; Qin W; Huang B; Chen W; Li S; Li J
    Biochem Biophys Res Commun; 2020 Jan; 522(1):21-25. PubMed ID: 31735335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Descriptive analysis of molecular subtypes in Tunisian breast cancer.
    Fourati A; Boussen H; El May MV; Goucha A; Dabbabi B; Gamoudi A; Sfar R; Rahal K; El May A; Ben Abdallah M
    Asia Pac J Clin Oncol; 2014 Jun; 10(2):e69-74. PubMed ID: 23176549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinctive role of SIRT1 expression on tumor invasion and metastasis in breast cancer by molecular subtype.
    Chung YR; Kim H; Park SY; Park IA; Jang JJ; Choe JY; Jung YY; Im SA; Moon HG; Lee KH; Suh KJ; Kim TY; Noh DY; Han W; Ryu HS
    Hum Pathol; 2015 Jul; 46(7):1027-35. PubMed ID: 26004371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence.
    Ortiz-Martínez F; Perez-Balaguer A; Ciprián D; Andrés L; Ponce J; Adrover E; Sánchez-Payá J; Aranda FI; Lerma E; Peiró G
    Hum Pathol; 2014 Mar; 45(3):504-12. PubMed ID: 24440093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.